Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: SARS-CoV-2 test, Urticaria, Vaccination site vesicles, Vaccination site warmth
Clinical narrative: Arm pain and swollen; Arm pain and swollen; warm to touch; blister at the injection site; rash; hives; red raise with itching appeared the next day slowly spread from abdomen to the back groin, inner thigh outer thigh to buttocks to the both arms from day one to 4 weeks; red raise with itching appeared the next day slowly spread from abdomen to the back groin, inner thigh outer thigh to buttocks to the both arms from day one to 4 weeks; This is a spontaneous report received from contactable reporter(s) (Nurse). The reporter is the patient.  A 53-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 20Sep2022 at 10:15 as dose 4 (booster), single (Lot number: GH9702) at the age of 53 years, in left arm for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: KENALOG [TRIAMCINOLONE ACETONIDE]; LIDOCAINE. Past drug history included: Ibuprofen, reaction(s): "Known allergies: Ibuprofen", notes: Known allergies: Ibuprofen. Vaccination history included: Bnt162b2 (Dose: 3 (Booster), Anatomical location: Arm left, Batch/Lot number: FF8841), for COVID-19 immunization; Bnt162b2 (Dose: 2, Anatomical location: Arm left, Batch/Lot number: EL3249), for COVID-19 immunization; Bnt162b2 (Dose: 1, Anatomical location: Arm left, Batch/Lot number: JP1685), for COVID-19 immunization. The following information was reported: PAIN IN EXTREMITY (non-serious), PERIPHERAL SWELLING (non-serious) all with onset 20Sep2022 at 20:00, outcome "recovered with sequelae" (2022) and all described as "Arm pain and swollen"; VACCINATION SITE VESICLES (non-serious) with onset 20Sep2022 at 20:00, outcome "recovered with sequelae" (2022), described as "blister at the injection site"; URTICARIA (non-serious) with onset 20Sep2022 at 20:00, outcome "recovered with sequelae" (2022), described as "hives"; RASH (non-serious) with onset 20Sep2022 at 20:00, outcome "recovered with sequelae" (2022); PRURITUS (non-serious), ERYTHEMA (non-serious) all with onset 20Sep2022 at 20:00, outcome "recovered with sequelae" (2022) and all described as "red raise with itching appeared the next day slowly spread from abdomen to the back groin, inner thigh outer thigh to buttocks to the both arms from day one to 4 weeks"; VACCINATION SITE WARMTH (non-serious) with onset 20Sep2022 at 20:00, outcome "recovered with sequelae" (2022), described as "warm to touch". The events "arm pain and swollen", "warm to touch", "blister at the injection site", "rash", "hives" and "red raise with itching appeared the next day slowly spread from abdomen to the back groin, inner thigh outer thigh to buttocks to the both arms from day one to 4 weeks" required physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of pain in extremity, peripheral swelling, vaccination site warmth, vaccination site vesicles, rash, urticaria, pruritus, erythema.  Additional information: No other vaccine in four weeks. Other medications in two weeks included Kenalog 1.5 cc + 0.5 c 1% Lidocaine injection. Adverse event: Arm pain and swollen, warm to touch, with blister at the injection site after 8 hours and last for a few days rash, hives, red raise with itching appeared the next day slowly spread from abdomen to the back groin, inner thigh outer thigh to buttocks to the both arms from day one to 4 weeks resulted in Doctor or other healthcare professional office/clinic visit. Treatment included Prednisone oral/triamcinolone 0.5% cream/Benadryl. Patient recovered with lasting effects.  No follow-up attempts are possible. No further information is expected.